Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR003230)
Formula
SVG example
Glucuronidation
Reactant Darolutamide Product Darolutamide metabolite M15a,15b
Reactant Info Product Info
Metabolic Type Conjugation - Glucuronidation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR003222 Darolutamide Ketodarolutamide Oxidation - Oxidation Darolutamide [1], [2], [3]
MR003228 Darolutamide Darolutamide metabolite M2 Conjugation - Glucuronidation Darolutamide [4]
MR003223 Darolutamide Darolutamide metabolite M31 Unclear Darolutamide [4]
MR003227 Darolutamide Darolutamide metabolite M32 Oxidation - N-Dealkylation Darolutamide [4]
MR003226 Darolutamide Darolutamide metabolite M33 Oxidation - N-Dealkylation Darolutamide [4]
MR003224 Darolutamide Darolutamide metabolite M34 Oxidation - N-Dealkylation Darolutamide [4]
MR003225 Darolutamide Darolutamide metabolite M36 Oxidation - N-Dealkylation Darolutamide [4]
MR003229 Darolutamide Darolutamide metabolite M7a,7b Conjugation - Glucuronidation Darolutamide [4]
References
1 Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer Clin Genitourin Cancer. 2018 Oct;16(5):332-340. doi: 10.1016/j.clgc.2018.07.017.
2 Drug-Drug Interaction Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Ipatasertib in Combination with Darolutamide in Patients with Advanced Prostate Cancer. Pharmaceutics. 2022 Oct 1;14(10):2101. doi: 10.3390/pharmaceutics14102101.
3 Clinical Pharmacokinetics of the Androgen Receptor Inhibitor Darolutamide in Healthy Subjects and Patients with Hepatic or Renal Impairment. Clin Pharmacokinet. 2022 Apr;61(4):565-575. doi: 10.1007/s40262-021-01078-y.
4 Metabolism and Mass Balance of the Novel Nonsteroidal Androgen Receptor Inhibitor Darolutamide in Humans Drug Metab Dispos. 2021 Jun;49(6):420-433. doi: 10.1124/dmd.120.000309.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.